John Lambert, ImmunoGen to Present at GTCbio’s Antibody Drug Conjugates Conference

Boston, MA, November 18, 2016 --(PR.com)-- John Lambert, Executive Vice President at ImmunoGen will give a presentation in the “Antibody Conjugate Therapeutics in Precision Medicine, Current Developments and Future Potential” session at GTCbio’s 2nd Antibody Drug Conjugates conference to be held on December 5-6, 2016 at the Hyatt Regency in Boston, MA.

John M. Lambert joined ImmunoGen as Senior Director of Research in 1987 and was promoted to Vice President, Research and Development in 1994, to Senior Vice President, Pharmaceutical Development in 2000, to Senior Vice President, Research and Development and Chief Scientific Officer in early 2008, and to Executive Vice President, Research and Development and Chief Scientific Officer in July 2008. In 2014 he was named Distinguished Research Fellow.

Prior to his tenure with ImmunoGen, Dr. Lambert was Assistant Professor of Pathology at the Dana-Farber Cancer Institute in Boston, MA. Dr. Lambert received his doctorate in Biochemistry from Cambridge University in England.

With the field of antibody drug conjugates rapidly expanding and the increasing number of ADC clinical trials, novel therapeutics are emerging. The ADC therapeutic area combines synthetic chemistry with rationale biology and is advancing monoclonal antibody treatments into the realm of precision medicine with improved effectiveness and therapeutic indices.

This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized healthcare, site specific attachment, and ADC therapeutics.

Sessions include:
I. Novel Payloads & Linkers in Antibody Drug Conjugates
II. Enhancing ADC Efficacy Through Combination Therapy with Immuno-oncology and Other Agents
III. Regulatory Trends & Challenges in Antibody Drug Conjugates
IV. Preclinical to Clinical Developments in ADC
V. Antibody Conjugate Therapeutics in Precision Medicine, Current Developments, and Future Potential

Don't miss important insights on how to overcome the many hurdles that are associated with the production of proteins.

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433